Ketamine Helps People Dislike Themselves Less
New research shows that ketamine reduces self-dislike, loosening the rigid prejudice toward oneself that can constitute depression.
Depression
Examining the Effects of Psychedelics on Experiential Avoidance
Experiential avoidance is one transdiagnostic process that may be implicated in the therapeutic benefits of psychedelics.
Ketamine-Induced Brain Rhythm Causes Dissociation: From Mice to Man
While ketamine produces a whole symphony of effects in the brain, surprisingly, a localized neural oscillation in a lesser-known area of the brain is enough to cause feelings of dissociation.
Psilocybin and Mindfulness for Depression: Complementary Actions Starting to Emerge
Both have long-lasting positive effects on mood, social skills and neuroplasticity. Combining them may potentiate and prolong mutual therapeutic effects.
Food for Thought: Can Psychedelics Boost Brain Growth Factor Levels?
Research suggests that BDNF can help rewire and overwrite stubborn neural pathways by creating new connections that facilitate more flexible and adaptive thoughts and behaviours. Psychedelics appear to tap into this mechanism.
THC and the 5-HT2A Receptor: What’s Going On?
THC binding to 5-HT2A may activate signaling pathways that cause negative effects on cognition and memory.
Psychedelic-Assisted Therapy in the Post-Pandemic Era
In the wake of Covid-19, psychedelic-assisted therapy is gaining attention.
Cybin’s Sublingual Psilocybin Strips Head to Clinical Trials for Dose-Finding
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
Examining the Cognitive Neuroscience of Psychedelics
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Psilocybin to Treat Anxiety and Depression in Cancer Patients
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.